August 19, 2017
A recent article suggests the CDC limit for blood lead may be lowered again. The logic for this is to base the limit on the 97.5th percentile of NHANES data, and to revisit the limit every 4 years. An article in Pediatrics has the details. Basically, the 97.5th percentile for blood lead has been decreasing – it was around 7 in 2000. And in the Pediatrics article it is stated that: “No safe blood lead concentration in children has been identified.” Nor has human physiology changed!
It’s hard to understand the logic behind the limit. If a child had a blood lead of 6 in 2011, the child was ok according to the CDC standard, but not ok in 2013. Similarly, a blood lead of 4 in 2016 was ok but not in 2017?
Here is a summary of lead standards in the USA through time.
1991 10 ug/dL
2012 5 ug/dL
2017? 3.48 ug/dL
August 13, 2017
Recently, I was asked to review an article, which I did. I thought the article was impressive but as usual I still recommended some ways to improve it. Upon resubmission, I reviewed it again – my recommendations were implemented – and the article was published (online first). But that’s not the end of the story. A while later I was asked to write a commentary about the article, which would be published along with the article.
In a sense, I had to review it again and this time was more critical. It was (and is) an impressive article but when my commentary is published, I have to be sure that I have written about all of the positive parts of the article and any remaining deficiencies. Hence I found new deficiencies!
It reminds me when I managed a group at Ciba Corning that I always insisted on a written rather than a verbal report. A verbal report is ephemeral but when you put your name on something you think about it much deeper.
July 26, 2017
I recently reviewed a paper for a journal and my recommendation was “accept with minor modifications”, whereby my suggestions for improvement were provided to the authors – as is usual. Eventually, the paper was resubmitted – my suggestions were implemented and I recommended “accept.” But I noticed that the other reviewer had recommended reject with no comments to the authors other than saying it was an article of limited interest. As a sometimes author I would have been pretty unhappy with such sparse feedback. I think authors deserve better.
July 26, 2017
These requests are not coming from Clinical Chemistry or similar journals. In the last two weeks, here is a list of journals requesting me to submit an article. Many (all?) require fees to publish your article.
Journal of Clinical Research and Ophthalmology
Open Access Journal of Diabetes
Endocrinological diabetes Clinical and Medical Research
Archives of Preventive Medicine
International Journal of Diabetes and Clinical Research
EC Diabetes and Metabolic Research
Journal of International Medical Research
European Journal of Biomedical and Pharmaceutical Sciences
Functional Foods in Health and Disease Journal
International Journal of Engineering Inventions
Journal of Palliative Care
Advances in Mechanical Engineering
Journal Cell Biology & Cell Metabolism
International Journal of Sports and Exercise Medicine
Therapeutic Advances in Endocrinology and Metabolism
International Journal of Computational Engneering Research
Journal of Research in Diabetes & Metabolism
July 12, 2017
When I was in industry, we would have a “release for sale” meeting in order to determine whether the product should be released or not. The person from regulatory affairs was always irksome because he always insisted the product was not ready for release. Yet, two hours or so later he signed the release for sale form. I think he behaved this way to show that 1) he was not some guy who would rubber stamp anything that was put in front of him and 2) if there were product problems he could say, he never wanted to release the product. But he nevertheless always looked bad because basically no new data had been put in front of him, yet he signed the release for sale form without someone putting a gun to his head. If he truly believed the product was not ready, he should have stuck to his guns.
But back to the title…, as a “concession” the marketing guy would say, ok let’s have a limited release for sale implying that fewer units would be delivered than possible. Of course, this was fiction – what the limited release really meant was marketing was limited to selling units as fast as they could, and because of startup issues, product sales usually took some time to get going.
On a more positive note, our release for sale meetings – as I recall – were always unanimous, and not every time was the decision to release – sometimes it was decided to not release the product.
July 11, 2017
I heard an advertisement from Alere which ended with the statement: knowing now matters. Unlike the vision and mission statements that I suffered through (and no longer remember) while I was in industry, the statement knowing now matters seems to be a perfect summation for a point of care company.